CVSCVS Health
$96.47-0.28%Real quote · delayedPharmacy & insurance🏛️ Company factsSEC filings + FINRA official data
Annual revenue $402.1B · latest quarter up 7.3% YoY · profitable (FY net income $1.8B) · short activity above its recent average — bears adding.
FY revenue
$402.1B
2025-12
Latest Q YoY
+7.3%
Gross margin
4.3%
FY net income
$1.8B
Diluted EPS
$1.4
Short volume
41.7%
20d avg 28.9% · shorts building
🐋 5%+ ownership filings (last 180d)
The parties below hold over 5% of this company and disclosed it to the SEC (mandatory in US markets). "Activist" filers state an intent to influence the company; "Passive" are pure investment positions.
- 2026-08-13passive (13G)DODGE & COX
- 2026-04-29passive (13G)VANGUARD CAPITAL MANAGEMENT LLC
- 2026-03-26passive (13G)VANGUARD GROUP INC
🎯 Market expectations
Expectation reliability High · 73/100Nasdaq analyst consensus · the pre-news baseline
- Jun 2026$2.58 vs $1.87+37.97%
- Mar 2026$2.57 vs $2.21+16.29%
- Dec 2025$1.09 vs $0.99+10.1%
- Sep 2025$1.60 vs $1.36+17.65%
The takeaway
This company habitually beats by +20.5% — the next report has to clear that bar to count as good news. Analysts cut estimates 4× in 4 weeks.
Analyst estimates, not our forecast · not investment advice
What's moving this stock lately
0 direct · 1 2nd-order · 0 thematicRanked by impact strength · strength = estimated move × freshness decay (shorter-lived effects decay faster)
As a pharmacy chain still facing opioid litigation, Walmart's settlement offers a reference point for potential liability size, easing market concerns over unresolved exposure
Also named: WMT · WBA
🕰️ Price × news · engine report card
Drag to pan, scroll to zoom · real daily bars and volume
📜 Call history (newest first
25 engine calls on this stock — each with direction, magnitude and its verified outcome · sign up to view
Sign up · free 7-day trial →Impact chains · crowding · conviction engine · insider signals — free 7-day trial on signup.
Sign up · free 7-day trial →